Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial.

Autor: Kosiborod MN; Saint Luke's Mid America Heart Institute, Kansas City, MO, USA; School of Medicine, University of Missouri-Kansas City, Kansas City, MO, USA; The George Institute for Global Health, University of New South Wales, Sydney, NSW, Australia. Electronic address: mkosiborod@saint-lukes.org., Esterline R; Late-stage Development, CVRM, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA., Furtado RHM; Academic Research Organization-Hospital Israelita Albert Einstein, Sao Paulo, Brazil; Instituto do Coracao do Hospital das Clinicas da FMUSP, Sao Paulo, Brazil., Oscarsson J; Late-stage Development, CVRM, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Gasparyan SB; Late-stage Development, CVRM, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Koch GG; Department of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA., Martinez F; National University of Córdoba, Córdoba, Argentina., Mukhtar O; Experimental Medicine and Immunotherapeutics Division, Department of Medicine, University of Cambridge, Cambridge, UK., Verma S; Division of Cardiac Surgery, Keenan Research Centre for Biomedical Science, Li Ka Shing Knowledge Institute of St Michael's Hospital, Toronto, ON, Canada; Department of Surgery and Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada., Chopra V; Max Super Speciality Hospital, New Delhi, India., Buenconsejo J; Late-stage Development, CVRM, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA., Langkilde AM; Late-stage Development, CVRM, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Ambery P; Late-stage Development, CVRM, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Tang F; Saint Luke's Mid America Heart Institute, Kansas City, MO, USA., Gosch K; Saint Luke's Mid America Heart Institute, Kansas City, MO, USA., Windsor SL; Saint Luke's Mid America Heart Institute, Kansas City, MO, USA., Akin EE; George Clinical Inc, Overland Park, KS, USA., Soares RVP; Academic Research Organization-Hospital Israelita Albert Einstein, Sao Paulo, Brazil., Moia DDF; Academic Research Organization-Hospital Israelita Albert Einstein, Sao Paulo, Brazil., Aboudara M; Division of Pulmonary and Critical Care, Saint Luke's Health System, Kansas City, MO, USA., Hoffmann Filho CR; Hospital Regional Hans Dieter Schmidt, Joinville, Brazil., Feitosa ADM; PROCAPE, Recife, Brazil., Fonseca A; Hospital Coracao do Brasil, Brasília, Brazil., Garla V; Department of Endocrinology, Diabetes and Metabolism, Internal Medicine, University of Mississippi Medical Center, Jackson, MS, USA; Mississippi Center for Clinical and Translational Research, Jackson, MI, USA., Gordon RA; North Shore University Health System, Evanston, IL, USA., Javaheri A; Washington University School of Medicine, St Louis, MO, USA., Jaeger CP; Hospital Mãe de Deus, Porto Alegre, Brazil., Leaes PE; Irmandade Da Santa Casa de Misericórdia de Porto Alegre, Brazil., Nassif M; Saint Luke's Mid America Heart Institute, Kansas City, MO, USA., Pursley M; Heart Group of the Eastern Shore, Fairhope, AL, USA., Silveira FS; Centro de Pesquisa Clínica do Coração, Aracaju, Brazil., Barroso WKS; Liga de Hipertensão Arterial -Universidade Federal de Goiás, Brazil; HCAMP-Secretaria Estadual de Saúde, Goiás, Brazil., Lazcano Soto JR; Instituto de Investigaciones Aplicadas a la Neurociencia AC, Durango City, Mexico., Nigro Maia L; Centro Integrado de Pesquisas, Hospital de Base, São José do Rio Preto, Brazil., Berwanger O; Academic Research Organization-Hospital Israelita Albert Einstein, Sao Paulo, Brazil.

Publikováno v: The lancet. Diabetes & endocrinology [Lancet Diabetes Endocrinol] 2021 Sep; Vol. 9 (9), pp. 586-594. Date of Electronic Publication: 2021 Jul 21.

Dapagliflozin and Kidney Outcomes in Hospitalized Patients with COVID-19 Infection: An Analysis of the DARE-19 Randomized Controlled Trial.

Autor: Heerspink HJL; University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.; The George Institute for Global Health, Newtown, NSW, Australia., Furtado RHM; Academic Research Organization, Hospital Israelita Albert Einstein, São Paulo, Brazil.; Instituto do Coracao do Hospital das Clinicas da FMUSP, São Paulo, Brazil., Berwanger O; Academic Research Organization, Hospital Israelita Albert Einstein, São Paulo, Brazil., Koch GG; Department of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina., Martinez F; National University of Córdoba, Córdoba, Argentina., Mukhtar O; Department of Medicine, Experimental Medicine and Immunotherapeutics Division, University of Cambridge, Cambridge, United Kingdom., Verma S; Division of Cardiac Surgery, Keenan Research Centre for Biomedical Science, Li Ka Shing Knowledge Institute of St. Michael's Hospital, Toronto, Ontario, Canada.; Department of Surgery and Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada., Gasparyan SB; Late-stage Development, CVRM, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Tang F; Saint Luke's Mid America Heart Institute, Kansas City, Missouri., Windsor SL; Saint Luke's Mid America Heart Institute, Kansas City, Missouri., de Souza-Dantas VC; Intensive Care Unit, University Hospital Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil., Del Sueldo M; Department of Cardiology, Clinica de Especialidades, Villa Maria, Argentina., Frankel R; Cardiology, Maimonides Medical Center, New York, New York., Javaheri A; Washington University School of Medicine, St Louis, Missouri., Maldonado RA; Nephrology and Transplantation Service, Clínica Privada Vélez Sarsfield, Postgraduate School of Nephrology, National University of Córdoba, Córdoba, Argentina., Morse C; Wake Forest School of Medicine, Winston-Salem, North Carolina., Mota-Gomes M; Centro Universitário Cesmac/Hospital do Coração de Alagoas, Maceió, Brazil., Shemin D; Division of Kidney Diseases and Hypertension, Alpert Medical School of Brown University, Providence, Rhode Island., Silva OL Jr; Centro Integrado de Pesquisas, Hospital de Base-São José do Rio Preto, São José do Rio Preto, Brazil., Tognon AP; Academic Research Organization, Hospital Israelita Albert Einstein, São Paulo, Brazil., Twahirwa M; Diabetes and Endocrinology Institute, Doctors Hospital at Renaissance, Edinburg, Texas., Buenconsejo J; Late-stage Development, CVRM, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland., Esterline R; Late-stage Development, CVRM, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland., Oscarsson J; Late-stage Development, CVRM, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Ambery P; Late-stage Development, CVRM, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Langkilde AM; Late-stage Development, CVRM, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Kosiborod MN; The George Institute for Global Health, Newtown, NSW, Australia.; Saint Luke's Mid America Heart Institute, Kansas City, Missouri.; School of Medicine, University of Missouri-Kansas City, Kansas City, Missouri.

Publikováno v: Clinical journal of the American Society of Nephrology : CJASN [Clin J Am Soc Nephrol] 2022 May; Vol. 17 (5), pp. 643-654. Date of Electronic Publication: 2022 Apr 28.

Oral and Injectable (Non-Insulin) Pharmacological Agents for the Treatment of Type 2 Diabetes

Autor: Feingold KR; Emeritus Professor of Medicine, University of California, San Francisco

Publikováno v: 2000.